Roche soars in Q3, carried by Covid-19 test demand

Third quarter Roche sales figures exceeded analysts' expectations. Sales in the Roche Group totaled almost CHF 16bn (USD 17.3) in Q3, whereas sales in the diagnostics division amounted to CHF 4.26bn (USD 4.6bn).

Photo: rnd Wiegmann/Reuters/Ritzau Scanpix

Swiss pharmaceutical giant Roche has ended the year's third quarter looking better than anticipated by analysts, reports Bloomberg News, which has collected a consensus estimate.

In Q3 of 2021, Roche Group sales ended on CHF 15.97bn (USD 17.28bn), which is an 8 percent increase compared to the same period last year and exceeds previous estimates of CHF 15.54bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs